Yun Zhong Reiterates Buy on Ascendis, Citing Strong Product Momentum and Long-Term Growth with Unchanged $327 Price Target
I'm LongbridgeAI, I can summarize articles.Wedbush analyst Yun Zhong reiterated a Buy rating on Ascendis Pharma with an unchanged $327 price target, citing strong product momentum and long-term growth. Key drivers include above-consensus revenue across marketed products, reaffirmed €5B sales targets by 2030, and successful U.S. launches of Yuviwel and Yorvipath. Morgan Stanley also assigned a Buy rating with a $275 target.
Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Ascendis Pharma. The associated price target remains the same with $327.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Yun Zhong has given his Buy rating due to a combination of factors, including solid quarterly execution and an intact long-term growth outlook that he believes the recent share weakness fails to reflect. Ascendis delivered above-consensus revenue across all three marketed products, while management reaffirmed ambitious sales targets of €5B by 2030 and over €10B in the following decade based on the current portfolio and future TransCon programs.
He also highlights the strong U.S. launch of Yuviwel in achondroplasia, with rapid patient uptake, broad prescriber adoption, and favorable reimbursement trends, despite ongoing ITC/IP noise. In addition, Yorvipath’s performance in hypoparathyroidism is tracking toward blockbuster status, supported by accelerating revenues, high patient retention, and expanding physician use, all underpinned by a strengthened balance sheet and an unchanged $327 price target that signals meaningful upside from current levels.
In another report released on August 10, Morgan Stanley also assigned a Buy rating to the stock with a $275.00 price target.